- Source : Press Release
- Date : 2021-04-29
- Event type : Phase 1
- Companies : Selecta Biosciences, Inc., Asklepios BioPharmaceutical, Inc., Bayer AG, SGS SA
Empty Capsid (SEL-399) Study Remains on Track
"The dose-escalation trial of SEL-399, an adeno-associated viral serotype 8 (AAV8) empty vector capsid (EMC-101) containing no DNA combined with ImmTOR, is currently underway and progressing as expected. The study, being conducted in healthy volunteers at the SGS Life Sciences Clinical Pharmacology Unit in Antwerp, Belgium, is designed to evaluate the safety and preliminary efficacy of ImmTOR in gene therapy. Selecta and AskBio intend to provide topline data in the fourth quarter of this year."
Sourced from the news: https://www.pharmacircle.com/one_news.php?id=589936